ROCKAWAY, N.J., April 28, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2022, after the close of the market on Thursday, May 5, 2022. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.
Thursday, May 5, 2022, 4:30 PM EDT
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13728177
Webcast: electroCore Earnings Webcast
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
Contact:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…
Mississauga, Ontario--(Newsfile Corp. - December 5, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), announced…
Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…
PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…
IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…